1 Pembrolizumab Plus Belzutifan Versus Pembrolizumab Plus Placebo as Adjuvant Therapy for Renal Cell Carcinoma: Patient-Reported Outcomes in LITESPARK-022 - Thomas B Powles; Toni K Choueiri; Jose A Karam; Cristina Suarez; Wesley Yip; Rana R McKay; Thomas Ferguson; Pooja Ghatalia; Christian Caglevic; Jad Chahoud; Roberto Iacovelli; Hans Hammers; et al. (The Oncologist, 2026)